Patient demographics and treatment summary
| Characteristic . | n (%) . |
|---|---|
| No. of patients | 220 |
| Female sex | 90 (41) |
| Age at nilotinib commencement, y | |
| Median | 55 |
| Range | 20-91 |
| Starting daily dose, mg | |
| 800 | 106 (48) |
| 600 | 90 (41) |
| 400 | 15 (7) |
| 300 | 6 (3) |
| 150 | 2 (1) |
| Not available | 1 (1) |
| Line of therapy | |
| First | 76 (35) |
| Second | 112 (51) |
| Third | 32 (14) |
| Follow-up from commencement, mo | |
| Median | 42 |
| Range | 6-117 |
| Characteristic . | n (%) . |
|---|---|
| No. of patients | 220 |
| Female sex | 90 (41) |
| Age at nilotinib commencement, y | |
| Median | 55 |
| Range | 20-91 |
| Starting daily dose, mg | |
| 800 | 106 (48) |
| 600 | 90 (41) |
| 400 | 15 (7) |
| 300 | 6 (3) |
| 150 | 2 (1) |
| Not available | 1 (1) |
| Line of therapy | |
| First | 76 (35) |
| Second | 112 (51) |
| Third | 32 (14) |
| Follow-up from commencement, mo | |
| Median | 42 |
| Range | 6-117 |